Akos F Pap
Overview
Explore the profile of Akos F Pap including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karaboyas A, Zhao J, Tanko L, Joergensen K, Pap A, Dasgupta I, et al.
J Am Heart Assoc
. 2024 Dec;
14(1):e033983.
PMID: 39719420
Background: People with kidney failure have a high risk of cardiovascular morbidity/death, including thromboembolic events. Factor XIa inhibitors are a new class of anticoagulants in development that may offer antithrombotic...
2.
Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches
Eikelboom J, Yi Q, McIntyre W, Bosch J, Whitlock R, Connolly S, et al.
Can J Cardiol
. 2024 Jul;
40(11):2171-2179.
PMID: 39002945
Background: Win ratio (WR) is a newer analytic approach for trials with composite end points that accounts for the relative importance of individual components. Our objective was to compare the...
3.
Yamada N, Fu W, Shi Z, Park K, Kim H, Dai X, et al.
Thromb J
. 2024 Jun;
22(1):48.
PMID: 38844941
Background: Risks of recurrence and major bleeding with extended anticoagulation in Asian patients with venous thromboembolism (VTE) are similar to those in non-Asian patients but risks according to baseline risk...
4.
Winkelmayer W, Lensing A, Thadhani R, Mahaffey K, Walsh M, Pap A, et al.
Kidney Int
. 2024 Mar;
106(1):145-153.
PMID: 38537676
Patients with kidney failure on hemodialysis (KF-HD) are at high risk for both atherothrombotic events and bleeding. This Phase IIb study evaluated the dose-response of fesomersen, an inhibitor of hepatic...
5.
Weitz J, Tanko L, Floege J, Fox K, Bhatt D, Thadhani R, et al.
Nat Med
. 2024 Feb;
30(2):435-442.
PMID: 38365952
Individuals with kidney failure undergoing hemodialysis are at elevated risk for thromboembolic events. Factor (F) XI, which is in the intrinsic pathway of coagulation, is emerging as an attractive target...
6.
Palumbo J, Lensing A, Brandao L, Hooimeijer H, Kenet G, van Ommen H, et al.
Blood Adv
. 2022 Aug;
6(22):5821-5828.
PMID: 36006613
Anticoagulant treatment of pediatric cancer-associated venous thromboembolism (VTE) has not been prospectively evaluated. Management of anticoagulation for cancer-associated VTE is often challenged by drug interactions and treatment interruptions. A total...
7.
Wiegers H, van Es J, Pap A, Lensing A, Middeldorp S, Scheres L
J Thromb Haemost
. 2021 Apr;
19(7):1759-1763.
PMID: 33829647
Background: It is unknown whether differences in clot structure and resolution contribute to the reported risk differences of recurrent venous thromboembolism (VTE) between men and women. Patients/methods: We used data...
8.
Boonyawat K, Lensing A, Prins M, Beyer-Westendorf J, Prandoni P, Martinelli I, et al.
Res Pract Thromb Haemost
. 2021 Mar;
5(2):308-313.
PMID: 33733030
Background: Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. Objectives: To demonstrate...
9.
Connor P, Sanchez van Kammen M, Lensing A, Chalmers E, Kallay K, Hege K, et al.
Blood Adv
. 2020 Dec;
4(24):6250-6258.
PMID: 33351120
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of...
10.
Hiatt W, Bonaca M, Patel M, Nehler M, Debus E, Anand S, et al.
Circulation
. 2020 Nov;
142(23):2219-2230.
PMID: 33138628
Background: The VOYAGER PAD trial (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated superiority of rivaroxaban plus aspirin versus...